Adenovirus as a new agent for multiple myeloma therapies: Opportunities and restrictions

Korean Journal of Hematology

Volumn 46, Issue 4, 2011, Pages 229-238

  Raus, Svjetlana ^a   Coin, Silvia ^a   Monsurrò, Vladia ^a,b  

^a UNIVERSITY OF VERONA   (Italy)

^b UNIVERSITY HOSPITAL OF VERONA   (Italy)

Author keywords

Adenovirus; Antiviral phenotype; Multiple myeloma; Oncolytic therapy

Indexed keywords

EID: 84859841942     PISSN: 17387949     EISSN: 20929129     Source Type: Journal    
DOI: 10.5045/kjh.2011.46.4.229     Document Type: Review

References (67)

1. Carli PM, Coebergh JW, Verdecchia A. Variation in survival of adult patients with haematological malignancies in Europe since 1978. Eur J Cancer 1998;34:2253-63.
2. Barlogie B, Epstein J, Selvanayagam P, Alexanian R. Plasma cell myeloma-new biological insights and advances in therapy. Blood 1989;73:865-79.
3. Kyle RA, Rajkumar SV. Multiple myeloma. Blood 2008;111: 2962-72.
4. Bhardwaj A, Sethi G, Vadhan-Raj S, et al. Resveratrol inhibits proliferation, induces apoptosis, and overcomes chemoresistance through down-regulation of STAT3 and nuclear factor-kappaBregulated antiapoptotic and cell survival gene products in human multiple myeloma cells. Blood 2007;109:2293-302.
5. Delforge M, Blade J, Dimopoulos MA, et al. Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues. Lancet Oncol 2010;11:1086-95.
6. Greipp P. Treatment paradigms for the newly diagnosed patient with multiple myeloma. Semin Hematol 2005;42(4 Suppl 4): S16-21.
7. Bluming AZ, Ziegler JL. Regression of Burkitt's lymphoma in association with measles infection. Lancet 1971;2:105-6.
8. Naschberger E, Werner T, Vicente AB, et al. Nuclear factor-kappaB motif and interferon-alpha-stimulated response element co-operate in the activation of guanylate-binding protein-1 expression by inflammatory cytokines in endothelial cells. Biochem J 2004;379:409-20.
9. Der SD, Zhou A, Williams BR, Silverman RH. Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays. Proc Natl Acad Sci U S A 1998; 95:15623-8.
10. Thirukkumaran CM, Nodwell MJ, Hirasawa K, et al. Oncolytic viral therapy for prostate cancer: efficacy of reovirus as a biological therapeutic. Cancer Res 2010;70:2435-44.
11. Shirakawa T. The current status of adenovirus-based cancer gene therapy. Mol Cells 2008;25:462-6.
12. Pesonen S, Kangasniemi L, Hemminki A. Oncolytic adenoviruses for the treatment of human cancer: focus on translational and clinical data. Mol Pharm 2011;8:12-28.
13. Liikanen I, Monsurro V, Ahtiainen L, et al. Induction of interferon pathways mediates in vivo resistance to oncolytic adenovirus. Mol Ther 2011;19:1858-66.
14. Bergelson JM, Cunningham JA, Droguett G, et al. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and Science 1997;275:1320-3.
15. Turturro F. Recombinant adenovirus-mediated cytotoxic gene therapy of lymphoproliferative disorders: is CAR important for the vector to ride? Gene Ther 2003;10:100-4.
16. Liu J, Li J, Su C, Huang B, Luo S. Soluble Fms-like tyrosine kinase-1 expression inhibits the growth of multiple myeloma in nude mice. Acta Biochim Biophys Sin (Shanghai) 2007;39:499-506.
17. Arendt BK, Ramirez-Alvarado M, Sikkink LA, et al. Biologic and genetic characterization of the novel amyloidogenic lambda light chain-secreting human cell lines, ALMC-1 and ALMC-2. Blood 2008;112:1931-41.
18. Senac JS, Doronin K, Russell SJ, Jelinek DF, Greipp PR, Barry MA. Infection and killing of multiple myeloma by adenoviruses. Hum Gene Ther 2010;21:179-90.
19. Teoh G, Chen L, Urashima M, et al. Adenovirus vector-based purging of multiple myeloma cells. Blood 1998;92:4591-601.
20. Fernandes MS, Gomes EM, Butcher LD, et al. Growth inhibition of human multiple myeloma cells by an oncolytic adenovirus carrying the CD40 ligand transgene. Clin Cancer Res 2009;15: 4847-56.
21. Ni H, Ergin M, Huang Q, et al. Analysis of expression of nuclear factor kappa B (NF-kappa B) in multiple myeloma: downregulation of NF-kappa B induces apoptosis. Br J Haematol 2001; 115:279-86.
22. Meeker TC, Lay LT, Wroblewski JM, Turturro F, Li Z, Seth P. Adenoviral vectors efficiently target cell lines derived from selected lymphocytic malignancies, including anaplastic large cell lymphoma and Hodgkin's disease. Clin Cancer Res 1997;3:357-64.
23. Tong AW, Seamour B, Chen J, et al. CD40 ligand-induced apoptosis is Fas-independent in human multiple myeloma cells. Leuk Lymphoma 2000;36:543-58.
24. Ren SP, Wang LS, Guo Q, et al. Genetically modified myeloma cell vaccine inducing antitumor immune response in vivo. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2006;14:54-60.
25. Thirukkumaran CM, Russell JA, Stewart DA, Morris DG. Viral purging of haematological autografts: should we sneeze on the graft? Bone Marrow Transplant 2007;40:1-12.
26. Kawa A, Arakawa S. The effect of attenuated vaccinia virus AS strain on multiple myeloma; a case report. Jpn J Exp Med 1987; 57:79-81.
27. Park BH, Hwang T, Liu TC, et al. Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial. Lancet Oncol 2008;9:533-42.
28. Goel A, Carlson SK, Classic KL, et al. Radioiodide imaging and radiovirotherapy of multiple myeloma using VSV(Delta51)-NIS, an attenuated vesicular stomatitis virus encoding the sodium iodide symporter gene. Blood 2007;110:2342-50.
29. Forsyth P, Roldán G, George D, et al. A phase I trial of intratumoral administration of reovirus in patients with histologically confirmed recurrent malignant gliomas. Mol Ther 2008;16:627-32.
30. Gollamudi R, Ghalib MH, Desai KK, et al. Intravenous administration of Reolysin, a live replication competent RNA virus is safe in patients with advanced solid tumors. Invest New Drugs 2010;28:641-9.
31. Vidal L, Pandha HS, Yap TA, et al. A phase I study of intravenous oncolytic reovirus type 3 Dearing in patients with advanced cancer. Clin Cancer Res 2008;14:7127-37.
32. Harrington KJ, Karapanagiotou EM, Roulstone V, et al. Two-stage phase I dose-escalation study of intratumoral reovirus type 3 dearing and palliative radiotherapy in patients with advanced cancers. Clin Cancer Res 2010;16:3067-77.
33. Myers RM, Greiner SM, Harvey ME, et al. Preclinical pharmacology and toxicology of intravenous MV-NIS, an oncolytic measles virus administered with or without cyclophosphamide. Clin Pharmacol Ther 2007;82:700-10.
34. Dingli D, Peng KW, Harvey ME, et al. Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter. Blood 2004;103:1641-6.
35. Msaouel P, Dispenzieri A, Galanis E. Clinical testing of engineered oncolytic measles virus strains in the treatment of cancer: an overview. Curr Opin Mol Ther 2009;11:43-53.
36. Peng KW, Donovan KA, Schneider U, Cattaneo R, Lust JA, Russell SJ. Oncolytic measles viruses displaying a single-chain antibody against CD38, a myeloma cell marker. Blood 2003;101:2557-62.
37. Au GG, Lincz LF, Enno A, Shafren DR. Oncolytic coxsackievirus A21 as a novel therapy for multiple myeloma. Br J Haematol 2007;137:133-41.
38. Rogers JM, Diana GD, McKinlay MA. Pleconaril. A broad spectrum antipicornaviral agent. Adv Exp Med Biol 1999;458: 69-76.
39. Rotbart HA. Antiviral therapy for enteroviral infections. Pediatr Infect Dis J 1999;18:632-3.
40. Surah S, O'Shea S, Dunn H, et al. Utilization of HIV point-of-care testing clinics in general practice and genitourinary medicine services in south-east London. Int J STD AIDS 2009;20:168-9.
41. Nayak S, Herzog RW. Progress and prospects: immune responses to viral vectors. Gene Ther 2010;17:295-304.
42. Seiler MP, Cerullo V, Lee B. Immune response to helper dependent adenoviral mediated liver gene therapy: challenges and prospects. Curr Gene Ther 2007;7:297-305.
43. Yamaguchi T, Kawabata K, Koizumi N, et al. Role of MyD88 and TLR9 in the innate immune response elicited by serotype 5 adenoviral vectors. Hum Gene Ther 2007;18:753-62.
44. Appledorn DM, McBride A, Seregin S, et al. Complex interactions with several arms of the complement system dictate innate and humoral immunity to adenoviral vectors. Gene Ther 2008;15: 1606-17.
45. Liu JM, Liu ZB, Zhu GH, et al. Determination of trace glucose and forecast of human diseases by affinity adsorption solid substrateroom temperature phosphorimetry based on triticum vulgaris lectin labeled with dendrimers-porphyrin dual luminescence molecule. Talanta 2008;74:625-31.
46. Muruve DA, Petrilli V, Zaiss AK, et al. The inflammasome recognizes cytosolic microbial and host DNA and triggers an innate immune response. Nature 2008;452:103-7.
47. Nociari M, Ocheretina O, Schoggins JW, Falck-Pedersen E. Sensing infection by adenovirus: Toll-like receptor-independent viral DNA recognition signals activation of the interferon regulatory factor 3 master regulator. J Virol 2007;81:4145-57.
48. Mastrangeli A, Harvey BG, Yao J, et al. "Sero-switch" adenovirusmediated in vivo gene transfer: circumvention of anti-adenovirus humoral immune defenses against repeat adenovirus vector administration by changing the adenovirus serotype. Hum Gene Ther 1996;7:79-87.
49. Dharmapuri S, Peruzzi D, Aurisicchio L. Engineered adenovirus serotypes for overcoming anti-vector immunity. Expert Opin Biol Ther 2009;9:1279-87.
50. Boo KH, Yang JS. Intrinsic cellular defenses against virus infection by antiviral type I interferon. Yonsei Med J 2010;51:9-17.
51. Sarkar SN, Sen GC. Novel functions of proteins encoded by viral stress-inducible genes. Pharmacol Ther 2004;103:245-59.
52. zum Büschenfelde CM, Metzger J, Hermann C, Nicklisch N, Peschel C, Bernhard H. The generation of both T killer and Th cell clones specific for the tumor-associated antigen HER2 using retrovirally transduced dendritic cells. J Immunol 2001;167: 1712-9.
53. Sadler AJ, Williams BR. Interferon-inducible antiviral effectors. Nat Rev Immunol 2008;8:559-68.
54. Sung RS, Qin L, Bromberg JS. TNFalpha and IFNgamma induced by innate anti-adenoviral immune responses inhibit adenovirusmediated transgene expression. Mol Ther 2001;3:757-67.
55. Wacher C, Muller M, Hofer MJ, et al. Coordinated regulation and widespread cellular expression of interferon-stimulated genes (ISG) ISG-49, ISG-54, and ISG-56 in the central nervous system after infection with distinct viruses. J Virol 2007;81:860-71.
56. Staeheli P, Pavlovic J. Inhibition of vesicular stomatitis virus mRNA synthesis by human MxA protein. J Virol 1991;65: 4498-501.
57. Krug RM, Shaw M, Broni B, Shapiro G, Haller O. Inhibition of influenza viral mRNA synthesis in cells expressing the interferon-induced Mx gene product. J Virol 1985;56:201-6.
58. Monsurró V, Beghelli S, Wang R, et al. Anti-viral state segregates two molecular phenotypes of pancreatic adenocarcinoma: potential relevance for adenoviral gene therapy. J Transl Med 2010;8:10.
59. Marincola FM, Wang E, Herlyn M, Seliger B, Ferrone S. Tumors as elusive targets of T-cell-based active immunotherapy. Trends Immunol 2003;24:335-42.
60. Tsai MH, Cook JA, Chandramouli GV, et al. Gene expression profiling of breast, prostate, and glioma cells following single versus fractionated doses of radiation. Cancer Res 2007;67: 3845-52.
61. Weichselbaum RR, Ishwaran H, Yoon T, et al. An interferonrelated gene signature for DNA damage resistance is a predictive marker for chemotherapy and radiation for breast cancer. Proc Natl Acad Sci U S A 2008;105:18490-5.
62. Martin DN, Boersma BJ, Yi M, et al. Differences in the tumor microenvironment between African-American and European-American breast cancer patients. PLoS One 2009;4:e4531.
63. Khodarev NN, Minn AJ, Efimova EV, et al. Signal transducer and activator of transcription 1 regulates both cytotoxic and prosurvival functions in tumor cells. Cancer Res 2007;67:9214-20.
64. Konstantinopoulos PA, Spentzos D, Cannistra SA. Geneexpression profiling in epithelial ovarian cancer. Nat Clin Pract Oncol 2008;5:577-87.
65. Andreu P, Colnot S, Godard C, et al. Identification of the IFITM family as a new molecular marker in human colorectal tumors. Cancer Res 2006;66:1949-55.
66. Györffy B, Dietel M, Fekete T, Lage H. A snapshot of microarraygenerated gene expression signatures associated with ovarian carcinoma. Int J Gynecol Cancer 2008;18:1215-33.
67. Hale BG, Randall RE, Ortín J, Jackson D. The multifunctional NS1 protein of influenza A viruses. J Gen Virol 2008;89:2359-76.